Employees: 210
Size Xvivo Perfusion (XVIVO.ST) is a Sweden Health Care company (Medical Specialties) with a market value of $611M, the 159th largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 197.20 on 18 Nov 2026.
Performance Over six months the shares fell 32.4%, against -6.6% for the median peer and +2.8% for the Sweden market (cap-weighted) — 4th lowest of 19 in its peer set.
Growth Revenue grew 17.8% over the last twelve months (peer median +16.1%); the operating margin is 12.1% (peer median 7.5%).
Valuation It trades at 53.1× forward earnings against a peer median of 21.1× (2nd most expensive of 14).
Price implies For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +35%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 5.5 points below its cost of capital (10.0% WACC).
Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | SEK 959M | SEK 812M | SEK 822M | SEK 598M | SEK 415M |
| Revenue growth | — | -1% | +38% | +44% | — |
| Gross profit | SEK 607M | SEK 533M | SEK 551M | SEK 417M | SEK 283M |
| EBITDA | SEK 199M | SEK 163M | SEK 183M | SEK 69.4M | SEK 34.3M |
| Net income | SEK 129M | SEK 25.2M | SEK 172M | SEK 91.8M | SEK 18.4M |
| Free cash flow | n/a | SEK 7.34M | SEK 40.6M | SEK 3.27M | SEK 9.67M |
| Capital expenditure | n/a | SEK 253M | SEK 193M | SEK 144M | SEK 131M |
| Total debt | SEK 121M | SEK 125M | SEK 34.0M | SEK 31.4M | SEK 10.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | XVIVO.ST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.1% | -3.4% | 4th lowest of 19 |
| 6-month return | -32.4% | -6.6% | 4th lowest of 19 |
| Distance from 52-week high | -37.4% | -30.1% | 7th lowest of 20 |
| Revenue growth (TTM) | +17.8% | +16.1% | 9th highest of 20 |
| Operating margin | 12.1% | 7.5% | 8th highest of 20 |
| Forward P/E | 53.1× | 21.1× | 2nd most expensive of 14 |
| Growth the price implies (Req g, 7 yrs) | 35.9% | 0.3% | most demanding of 11 |
| Growth delivered (Del g) | +35.2% | +13.1% | 2nd highest of 11 |
| Hurdle (Req g minus delivered) | +0.7 pp | -13.2 pp | 3rd most demanding of 11 |
| ROIC minus cost of capital | -5.5 pp | +1.2 pp | 6th lowest of 19 |
| EV / EBITDA | 30.3× | 13.2× | 2nd most expensive of 8 |
| Net debt / EBITDA | -1.0× | -0.7× | 4th least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Xvivo Perfusion XVIVO.ST | Sweden | $611M | -32% | +18% | 12% | 53.1× | 35.9% | +35.2% |
| Beijing Chunlizhengda Medical Instruments 688236.SS | China | $618M | -27% | -13% | 31% | 17.4× | -8.5% | +2.2% |
| Nanosonics NAN.AX | Australia | $599M | -4% | +3% | 7% | 98.6× | 35.3% | +6.7% |
| Medistim MEDI.OL | Norway | $599M | +32% | +19% | 29% | 31.8× | -1.2% | +14.5% |
| Sight Sciences SGHT | United States | $599M | +122% | +16% | -30% | n/a | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $595M | n/a | n/a | n/a | n/a | n/a | n/a |
| vVARDIS VVVV | United States | $594M | n/a | +148% | -72% | n/a | n/a | n/a |
| SunMax Biotechnology 4728.TWO | Taiwan | $630M | 0% | +19% | 51% | n/a | -2.6% | +18.8% |
| Tactile Systems Technology TCMD | United States | $592M | +6% | +14% | 9% | 21.1× | 8.4% | +12.0% |
| Hangzhou AGS MedTech 688581.SS | China | $590M | -22% | -18% | 33% | 18.9× | 0.4% | +27.8% |
| Ningbo David Medical Device 300314.SZ | China | $589M | +25% | +19% | 11% | 12.0× | n/a | n/a |
| Orchestra BioMed OBIO | United States | $587M | +87% | +1,007% | -195% | n/a | n/a | n/a |
| AK Medical 1789.HK | Hong Kong | $642M | -23% | +16% | 26% | 10.5× | -11.5% | +6.7% |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $575M | -38% | +6% | 8% | 39.7× | n/a | n/a |
| Pacific Biosciences of California PACB | United States | $573M | +54% | +4% | -98% | n/a | n/a | n/a |
| QuidelOrtho QDEL | United States | $657M | -20% | -5% | -2% | 10.7× | n/a | n/a |
| Synektik SNT.WA | Poland | $662M | +10% | +32% | 24% | 13.8× | 0.2% | +47.5% |
| Shanghai Kinetic Medical 300326.SZ | China | $662M | -10% | -28% | 17% | 26.0× | 6.6% | -1.9% |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $563M | -57% | +28% | 7% | 33.7× | n/a | n/a |
| Cowealth Medical China 603122.SS | China | $562M | -34% | -18% | -5% | n/a | n/a | n/a |
| Shenzhen Sunnypol Optoelectornics 002876.SZ | China | $680M | -9% | +29% | 5% | 39.0× | 10.1% | +14.2% |